FDA approvals for Novartis’ Kymriah™ and Kite’s Yescarta™ in 2017 ushered in a new era of medical treatments using cell and gene therapies. Transporting these high value, unique, and often irreplaceable autologous cells from point of collection, to processing center, and back to the patient for administration calls for a paradigm change to the traditional…
On April 9, 2018 BioLife Solutions Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade biopreservation media, (“BioLife” or the “Company”), announced that Casdin Capital LLC, (“Casdin”) a New York-based, life science-focused investment firm, has entered into an agreement to purchase 1,000,000 BioLife Solutions common shares in a private transaction from the Company’s second…
On April 2, 2018, BioLife Solutions Inc. (NASDAQ: BLFS) (“BioLife”), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media, announced preliminary revenue for the three months ended March 31, 2018. First quarter 2018 preliminary revenue from sales of BioLife’s proprietary CryoStor® and HypoThermosol® biopreservation media products reached $3.8 million,…
12 Additional Pending Patent Applications Submitted for evo® Smart Shippers, Liquid Nitrogen Dry Vapor Shippers and Cold Chain SaaS Application On March 26, 2018 BioLife Solutions Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media, and SAVSU Technologies, the leading developer of smart,…
On March 20, 2018 Dr. Brian Hawkins, Scientific Applications Director, will be presenting a poster entitled, “The prats and pitfalls of assessing cell viability after cryopreservation,” at the 2018 PDA Annual Meeting in Orlando, FL. The poster describes how common methods of determining cell viability under normal conditions are inconsistent and inaccurately represent cell health…
On March 13, 2018 BioLife Solutions Inc. (NASDAQ: BLFS) (“BioLife”), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media, announced that the performance of its proprietary, cGMP CryoStor cell freeze media was reported in the journal Laboratory Investigation. In multiple comparisons of preservation efficacy of patient-derived xenograft (PDX) tumors,…
Wang X, Popplewell L, Wagner J, Naranjo A, Blanchard M, Mott M, Norris A, Wong C, Urak R, Chang W, Khaled S, Siddiqi T, Budde L, Xu J, Chang B, Gidwaney N, Thomas S, Cooper L, Riddell S, Brown C, Jensen M, Forman S. Phase 1 studies of central memory–derived CD19 CAR T–cell therapy following…
